The Correlation between Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Insulin Resistance and the Components of Atherogenic Lipoprotein Phenotype in Males with Central Obesity
BACKGROUND: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) promotes the degradation of LDL receptor in hepatocytes. in vitro studies have proven that insulin increases the expression of PCSK9. Insulin resistance, a common condition in central obesity is characterized by dyslipidemia called At...
Main Authors: | Yusmiati Yusmiati, Burhanuddin Bahar, Andi Wijaya |
---|---|
Format: | Article |
Language: | English |
Published: |
Secretariat of The Indonesian Biomedical Journal
2010-12-01
|
Series: | Indonesian Biomedical Journal |
Online Access: | http://inabj.org/index.php/ibj/article/view/128 |
Similar Items
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01) -
THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
by: Алексей Михайлович Чаулин, et al.
Published: (2019-12-01) -
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
by: Xuhui Bao, et al.
Published: (2024-01-01) -
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
by: Emma M. O’Connell, et al.
Published: (2020-06-01) -
Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
by: Thomas S. Metkus, et al.
Published: (2022-06-01)